No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Rossi, E., Schinzari, G., Zizzari, I. G., Maiorano, B. A., Pagliara, M. M., Sammarco, M. G., Fiorentino, V., Petrone, G., Cassano, A., Rindi, G., Bria, E., Blasi, M. A., Nuti, M., Tortora, G., Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy?, <<CANCERS>>, 2019; 11 (8): 1055-1066. [doi:10.3390/cancers11081055] [http://hdl.handle.net/10807/147729]
Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy?
Rossi, Ernesto;Schinzari, Giovanni;Maiorano, Brigida Anna;Pagliara, Monica Maria;Fiorentino, Vincenzo;Petrone, Gianluigi;Cassano, Alessandra;Rindi, Guido;Bria, Emilio;Blasi, Maria Antonietta;Tortora, Giampaolo
2019
Abstract
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
